» Articles » PMID: 16357514

Cytotoxicity of a Natural Anthraquinone (Aloin) Against Human Breast Cancer Cell Lines with and Without ErbB-2: Topoisomerase IIalpha Coamplification

Overview
Specialties Oncology
Pharmacology
Date 2005 Dec 17
PMID 16357514
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

In the present study the cytotoxic activity of aloin, a natural anthracycline from Aloe plant, is reported against two human breast cancer cell lines; without (MCF-7) and with (SKBR-3) erbB-2-topoIIalpha coamplification. MCF-7cell line was shown to be more sensitive to aloin than SKBR-3 demonstrated by MTT and clonogenic assays, from which IC50 and 50% ICF values are reported to be 60 microg/ml, respectively, in the former cell line and as high as 150 and 80 microg/ml, respectively, in the latter, which are still far below the maximum tolerated dose of the compound. The effect of aloin is suggested to be brought about by more than one mechanism depending on the dose level and tumor phenotype. This was demonstrated by flow cytometric analysis, fluorescence microscopy and western blot analysis, which revealed that aloin at higher concentrations caused a reduction in the proportion of cells undergoing mitosis by induction of apoptosis, inhibition of topo II alpha protein expression and downregulation of cyclin B1 protein expression in MCF-7 cell line, whereas erbB-2 protein expression was not affected. Topo IIalpha protein expression was mildly downregulated in SKBR-3 cell line at higher concentrations only.

Citing Articles

Exploring the therapeutic potential of Aloin: unraveling neuroprotective and anticancer mechanisms, and strategies for enhanced stability and delivery.

Zimbone S, Romanucci V, Zarrelli A, Giuffrida M, Sciacca M, Lanza V Sci Rep. 2024; 14(1):16731.

PMID: 39030250 PMC: 11271566. DOI: 10.1038/s41598-024-67397-9.


Evaluation of oyster mushroom ()-derived anthraquinone on the induction of apoptosis and suppression of MMP-2 and MMP-9 expression in breast cancer cells.

Jayaprakash B, Suresh A, Thiruvengadam R, Alharbi N, Kadaikunnan S, Sankaran S Int J Med Sci. 2024; 21(6):1016-1026.

PMID: 38774755 PMC: 11103395. DOI: 10.7150/ijms.93334.


HMGB1/RAGE axis in tumor development: unraveling its significance.

Fan A, Gao M, Tang X, Jiao M, Wang C, Wei Y Front Oncol. 2024; 14:1336191.

PMID: 38529373 PMC: 10962444. DOI: 10.3389/fonc.2024.1336191.


Therapeutic Potential of 1,8-Dihydroanthraquinone Derivatives for Breast Cancer.

Okon E, Gawel-Beben K, Jarzab A, Koch W, Kukula-Koch W, Wawruszak A Int J Mol Sci. 2023; 24(21).

PMID: 37958772 PMC: 10648492. DOI: 10.3390/ijms242115789.


Identification of natural products and FDA-approved drugs for targeting cancer stem cell (CSC) propagation.

Bonuccelli G, Sotgia F, Lisanti M Aging (Albany NY). 2022; 14(23):9466-9483.

PMID: 36455875 PMC: 9792210. DOI: 10.18632/aging.204412.